Efficacy of lamivudine in HBeAg-negative chronic hepatitis B

Journal of Medical Virology

Volumn 66, Issue 4, 2002, Pages 435-451

  Dahmen, Anja ^a   Herzog Hauff, Sabine ^a   Böcher, Wulf O ^a   Galle, Peter R ^a   Löhr, Hanns F ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Breakthrough infection; Pre core HBV; YMDD

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHAN1 INTERFERON; GANCICLOVIR; HEPATITIS B ANTIBODY; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PLACEBO; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ANTIVIRAL ACTIVITY; ARTICLE; ASIA; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER HISTOLOGY; LONG TERM CARE; RELAPSE; SOUTHERN EUROPE; TREATMENT OUTCOME; VIRUS LOAD; VIRUS MUTANT;

ANTIVIRAL AGENTS; CLINICAL TRIALS; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

HEPATITIS B VIRUS;

EID: 0036195781     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.2164     Document Type: Article

References (90)

1. Detection of pre-core hepatitis B virus mutants in asymptomatic HBsAg-positive family members
2. Interferon plus lamivudine therapy for patients with chronic hepatitis B with and without HBeAg who relapsed after interferon treatment
3. Randomised trial in HBeAg negative patients with replicating virus with ganciclovir vs lamivudine in combination with interferon. Evaluation of long-term efficacy
4. Identification and characterisation of mutations in hepatitis B virus resistant to lamivudine
5. One year treatment of chronic hepatitis B (CHB) with lamivudine: Biochemical, virological, and histological results
6. Hepatitis B virus pre-core mutant infection is associated with severe recurrent disease after liver transplantation
7. Clinical significance of YMDD mutant hepatitis B virus (HBV) in a large cohort of lamivudine-treated hepatitis B patients
8. Efficacy of lamivudine in patients with hepatitis B virus pre-core mutant infection before and after liver transplantation
9. Efficacy of lamivudine on replication of hepatitis B in HIV-infected patients
10. Identification of HBV mutants which cannot produce pre-core derived HBeAg and may be responsible for severe hepatitis
11. Natural course and response of interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen
12. Wild-type and e antigen-deficient hepatitis B viruses and course of chronic hepatitis B
13. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B
14. Different incidence of genotypic resistance to lamivudine in chronic hepatitis B between HBeAg and anti-HBe positive patients
15. Reversion from pre-core mutation to wild type in anti-HBe positive patients on lamivudine therapy
16. Two years of lamivudine therapy in patients with chronic hepatitis B. Analysis of efficacy and emergence of HBV genomic variations
17. Lamivudine treatment for patients with HBeAg-negative decompensated liver disease
18. Interferon for chronic hepatitis B: A meta-analysis of randomised controlled trials
19. Cellular metabolism of (-) enantiomeric 2′-deoxy-3′ thiacytidine
20. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection
21. Different hepatitis B virus genotypes are associated with different mutation in the core promoter and pre-core regions during hepatitis B e antigen seroconversion
22. Biochemical pharmacology of (+) and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents
23. Enhanced HBeAg seroconversion rates in Chinese patients on lamivudine
24. Incremental increases in HBeAg seroconversion and continued ALT normalisation in Asian chronic HBV (CHB) patients treated with lamivudine for four years
25. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by type after cessation of therapy
26. The effect of lamivudine in Korean patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 6 months
27. The separated enantiomers of 2-deoxy-3-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro
28. Resistance to lamivudine in patients with chronic hepatitis B with and without HBeAg
29. DNA polymerase activity of hepatitis B virus particles: Differential inhibition by L-enantiomers of nucleotide analogs
30. Efficacy of prolonged lamivudine therapy in HBV DNA/HBeAb positive previously non responder chronic hepatitis B
31. Lamivudine as initial treatment for chronic hepatitis B in the United States
32. Extended lamivudine treatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy
33. Efficacy of long-term lamivudine monotherapy in HBeAg negative chronic hepatitis B
34. Interferon alfa and lamivudine in patients with chronic hepatitis B anti-HBe positive
35. Natural history and prognostic factors for chronic hepatitis B
36. A randomized controlled trial of lymphoblastoid interferon-α in patients with chronic hepatitis B lacking HBeAg
37. Epidemiology of HBeAg negative chronic hepatitis B (e-CHB) in the Asia Pacific Region
38. Worldwide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants
39. The anti-hepatitis B activities, cytotoxicities, and anabolic profile of the (-) and (+) enantiomers of cis-5-fiuoro-1-[2-hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine
40. Lamivudine in anti-HBeAg positive chronic hepatitis B: Response after one year of treatment
41. Low-dose recombinant interferon therapy in anti-HBe positive chronic hepatitis B in Asian Indians
42. Hepatitis B e antigen negative chronic hepatitis B: From clinical recognition to pathogenesis and treatment
43. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B
44. Efficacy of long term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B
45. Long term follow-up of chronic hepatitis B patients after interferon treatment
46. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy
47. The treatment of chronic viral hepatitis
48. Effects of serum albumin on response and relapse to lamivudine in patients with chronic hepatitis B
49. Efficacy and safety of long term treatment of chronic hepatitis B with IFNα plus lamivudine versus IFNα alone
50. Response to Interferon alpha 2a in patients with e antigen-negative chronic hepatitis B
51. Hepatitis B virus X gene 1751 to 1764 mutations: Implications for HBeAg status and disease
52. A one-year trial of lamivudine for chronic hepatitis B
53. A randomised, controlled trial of a 24 month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis Be antigen in serum
54. Features of response and resistance to lamivudine in patients with chronic patients with chronic hepatitis B with and without HbeAg
55. Three year lamivudine therapy in chronic HBV
56. Hepatitis B virus pre-core mutation and fulminant hepatitis in the United States. A polymerase chain reaction-based assay for the detection of specific mutation
57. The development of cirrhosis in patients with chronic type B hepatitis: A prospective study
58. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
59. Hepatitis B virus carriers without pre-core mutations in hepatitis B e antigen-negative stage show more severe liver damage
60. Reversion from pre-core stop codon mutation to wild type sequence in HBeAg-patients who develop lamivudine resistant HBV gene mutations
61. Efficacy of prolonged interferon-alpha treatment in chronic hepatitis B patients with HBeAb: Comparison between 6 and 12 months of therapy
62. Lamivudine improves liver function in patients with de-compensated cirrhosis resulting from HBeAg Negative/HBV DNA positive chronic hepatitis B
63. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus pre-core mutant-associated infection: High resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin
64. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
65. Lamivudine without HBIg for prevention of graft re-infection by hepatitis B: Long-term follow-up
66. Pre-core mutant hepatitis B virus-infection and liver disease
67. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen
68. Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon
69. HBV reactivation and biochemical breakthroughs after initially effective lamivudine therapy in patients with pre-core mutant HBV related liver disease
70. Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon
71. Benefits of extended lamivudine treatment in patients with HBeAg-negative HBV DNA-positive (pre-core mutant) chronic hepatitis B (CHB)
72. Prevalence and type of pre-C HBV mutants in anti-HBe positive carriers with chronic liver disease in a highly endemic area
73. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine
74. Long term lamivudine treatment in anti-HBe positive chronic hepatitis B: An interim analysis
75. Twelve months of lamivudine/interferon combination therapy prevents the appearance of YMDD mutants in patients with anti-HBe positive chronic hepatitis B: A controlled pilot study
76. Chronic hepatitis B
77. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy
78. Efficacy of treatment with lamivudine in patients with chronic active E-minus variant hepatitis B virus infection: A non-randomized, open label study
79. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2′-3′-dideoxy-3′-thiacytidine
80. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection
81. +) chronic hepatitis B
82. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (pre-core mutant) chronic hepatitis B
83. Post lamivudine treatment follow-up of patients with HBeAg negative chronic hepatitis B
84. The emergence of envelope and pre-core/core mutants of hepatitis B virus: The potential role of antibody selection
85. Emergence of lamivudine resistant HBV is not always associated with HBeAg positive status or a high pre-treatment viral load in patients with chronic infection
86. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: A meta-analysis
87. Use of lamivudine in Chinese patients with hepatitis B E-antigen negative chronic hepatitis B
88. Dynamics of hepatitis B virus infections in vivo
89. Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B